JPMORGAN CHASE & CO - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 86 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$1,618,748
+105.7%
54,430
+24.6%
0.00%
Q2 2023$787,005
+20.9%
43,674
+7.8%
0.00%
Q1 2023$651,000
+102258.5%
40,513
+16.8%
0.00%
Q4 2022$636
-99.9%
34,694
+6.1%
0.00%
Q3 2022$642,000
+11.5%
32,690
+5.8%
0.00%
Q2 2022$576,000
-67.9%
30,889
-62.2%
0.00%
Q1 2022$1,793,000
+30.7%
81,736
+69.3%
0.00%
Q4 2021$1,372,000
+182.3%
48,273
+109.3%
0.00%
Q3 2021$486,000
+28.2%
23,060
+14.5%
0.00%
Q2 2021$379,000
-63.1%
20,141
-70.0%
0.00%
Q1 2021$1,026,000
-7.9%
67,104
-15.1%
0.00%
Q4 2020$1,114,000
+632.9%
79,008
+683.3%
0.00%
Q3 2020$152,000
-5.0%
10,087
+10.4%
0.00%
Q2 2020$160,000
+201.9%
9,135
+150.1%
0.00%
Q1 2020$53,000
-44.2%
3,653
-2.8%
0.00%
Q4 2019$95,000
+69.6%
3,759
+0.6%
0.00%
Q3 2019$56,000
-25.3%
3,737
+23.2%
0.00%
Q2 2019$75,000
+56.2%
3,033
+45.3%
0.00%
Q1 2019$48,000
-9.4%
2,087
+17.2%
0.00%
Q4 2018$53,000
+15.2%
1,780
+10.4%
0.00%
Q3 2018$46,0001,6130.00%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q4 2020
NameSharesValueWeighting ↓
Saturn V Capital Management LP 623,819$11,336,5019.41%
Finepoint Capital LP 822,745$15,0564.87%
Bain Capital Life Sciences Investors, LLC 2,305,558$42,1924.72%
Opaleye Management Inc. 732,000$13,395,6004.66%
5AM Venture Management, LLC 862,286$15,779,8344.24%
SPHERA FUNDS MANAGEMENT LTD. 671,644$12,291,0852.64%
First Light Asset Management, LLC 1,329,313$24,326,4282.26%
BRAIDWELL LP 3,469,674$63,495,0342.13%
BVF INC/IL 2,736,613$50,080,0182.11%
Perceptive Advisors 4,039,276$73,918,7512.08%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders